Ruby Lieshout

Ruby Lieshout

Auto-generated profile, based on publicly available information

Ruby Lieshout

Department of Surgery, Erasmus MC Transplant Institute, Erasmus MC University Medical Center Rotterdam the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LBLaura Broutier
Laura Broutier
GMGianmarco Mastrogiovanni
Gianmarco Mastrogiovanni
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen
HFHayley E Francies
Hayley E Francies
LGLena Morrill Gavarró
Lena Morrill Gavarró
MHMeritxell Huch
Meritxell Huch
Tumor organoids derived from the most common subtypes of primary liver cancer recapitulate the histologic and molecular features of the tissues of origin, even after long-term culture. These in vitro models, as well as those for colorectal cancer reported in Crespo et al. in a previous issue, are amenable for drug screening and allow the identification of therapeutic approaches with potential for cancer treatment. Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a novel, near-physiological organoid culture system, wherein primary human healthy liver cells form long-term expanding organoids that retain liver tissue function and genetic stability. Here we extend this culture system to the propagation of primary liver cancer (PLC) organoids from three of the most common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and combined HCC/CC (CHC) tumors. PLC-derived organoid cultures preserve the histological architecture, gene expression and genomic landscape of the original tumor, allowing for discrimination between different tumor tissues and subtypes, even after long-term expansion in culture in the same medium conditions. Xenograft studies demonstrate that the tumorogenic potential, histological features and metastatic properties of PLC-derived organoids are preserved in vivo. PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer. We thus demonstrate the wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease.

21 May 2022 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
GZGuoying Zhou
Guoying Zhou
RLRuby Lieshout
Ruby Lieshout
GTGilles S. van Tienderen
Gilles S. van Tienderen
VRValeska de Ruiter
Valeska de Ruiter
MRMartin Van Royen
Martin Van Royen
JKJaap Kwekkeboom
Jaap Kwekkeboom
Background: Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI will be effective for individual patients. Therefore, the aim of this study is to develop a co-culture method with patient-derived CCA organoids and immune cells, which could represent anti-cancer immunity in vitro. Methods: CCA organoids were co-cultured with peripheral blood mononuclear cells or T cells. Flow cytometry, time-lapse confocal imaging for apoptosis, and quantification of cytokeratin 19 fragment (CYFRA) release were applied to analyse organoid and immune cell behaviour. CCA organoids were also cultured in immune cell-conditioned media to analyse the effect of soluble factors. Results: The co-culture system demonstrated an effective anti-tumour organoid immune response by a decrease in live organoid cells and an increase in apoptosis and CYFRA release. Interpatient heterogeneity was observed. The cytotoxic effects could be mediated by direct cell–cell contact and by release of soluble factors, although soluble factors only decreased viability in one organoid line. Conclusions: In this proof-of-concept study, a novel CCA organoid and immune cell co-culture method was established. This can be the first step towards personalised immunotherapy for CCA by predicting which ICIs are most effective for individual patients.

4 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
MLMeng Li
Meng Li
LWLing Wang
Ling Wang
YWYijin Wang
Yijin Wang
SZShaoshi Zhang
Shaoshi Zhang
GZGuoying Zhou
Guoying Zhou
QPQiuwei Pan
Qiuwei Pan
Metabolic reprogramming universally occurs in cancer. Mitochondria act as the hubs of bioenergetics and metabolism. The morphodynamics of mitochondria, comprised of fusion and fission processes, are closely associated with mitochondrial functions and are often dysregulated in cancer. In this study, we aim to investigate the mitochondrial morphodynamics and its functional consequences in human liver cancer. We observed excessive activation of mitochondrial fusion in tumor tissues from hepatocellular carcinoma (HCC) patients and in vitro cultured tumor organoids from cholangiocarcinoma (CCA). The knockdown of the fusion regulator genes, OPA1 (Optic atrophy 1) or MFN1 (Mitofusin 1), inhibited the fusion process in HCC cell lines and CCA tumor organoids. This resulted in inhibition of cell growth in vitro and tumor formation in vivo, after tumor cell engraftment in mice. This inhibitory effect is associated with the induction of cell apoptosis, but not related to cell cycle arrest. Genome-wide transcriptomic profiling revealed that the inhibition of fusion predominately affected cellular metabolic pathways. This was further confirmed by the blocking of mitochondrial fusion which attenuated oxygen consumption and cellular ATP production of tumor cells. In conclusion, increased mitochondrial fusion in liver cancer alters metabolism and fuels tumor cell growth.

1 April 2017 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
JWJorke Willemse
Jorke Willemse
RLRuby Lieshout
Ruby Lieshout
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen

9 March 2019 in Liver International
Verified
Journal Article
Open access
PDF file
SVSilvestre Vicent
Silvestre Vicent
RLRuby Lieshout
Ruby Lieshout
ASAnna Saborowski
Anna Saborowski
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen
CRChiara Raggi
Chiara Raggi
VCVincenzo Cardinale
Vincenzo Cardinale
Human cholangiocarcinoma (CCA) is an aggressive tumour entity arising from the biliary tree, whose molecular pathogenesis remains largely undeciphered. Over the last decade, the advent of high‐throughput and cell‐based techniques has significantly increased our knowledge on the molecular mechanisms underlying this disease while, at the same time, unravelling CCA complexity. In particular, it becomes clear that CCA displays pronounced inter‐ and intratumoural heterogeneity, which is presumably the consequence of the interplay between distinct tissues and cells of origin, the underlying diseases, and the associated molecular alterations. To better characterize these events and to design novel and more effective therapeutic strategies, a number of CCA experimental and preclinical models have been developed and are currently generated. This review summarizes the current knowledge and understanding of these models, critically underlining their translational usefulness and limitations. Furthermore, this review aims to provide a comprehensive overview on cells of origin, cancers stem cells and their dynamic interplay within CCA tissue.

18 November 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
LNLuan Nguyen
Luan Nguyen
MJMyrthe Jager
Myrthe Jager
RLRuby Lieshout
Ruby Lieshout
PRPetra E. de Ruiter
Petra E. de Ruiter
MLMauro D. Locati
Mauro D. Locati
EKEwart Kuijk
Ewart Kuijk
Inflammatory liver disease increases the risk of developing primary liver cancer. The mechanism through which liver disease induces tumorigenesis remains unclear, but is thought to occur via increased mutagenesis. Here, we performed whole-genome sequencing on clonally expanded single liver stem cells cultured as intrahepatic cholangiocyte organoids (ICOs) from patients with alcoholic cirrhosis, non-alcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC). Surprisingly, we find that these precancerous liver disease conditions do not result in a detectable increased accumulation of mutations, nor altered mutation types in individual liver stem cells. This finding contrasts with the mutational load and typical mutational signatures reported for liver tumors, and argues against the hypothesis that liver disease drives tumorigenesis via a direct mechanism of induced mutagenesis. Disease conditions in the liver may thus act through indirect mechanisms to drive the transition from healthy to cancerous cells, such as changes to the microenvironment that favor the outgrowth of precancerous cells.